Peptide Price Finder

Home · Research · Growth hormone

CJC-1295 (no DAC) research

What published studies found for CJC-1295 (no DAC): 6 papers, 3 in humans, with sample sizes and key results, plus 1 registered clinical trials.

D
Little or no evidence
Why: No efficacy studies of the modified GRF(1-29) itself; human data are small uncontrolled trials of the unmodified parent peptide GHRH(1-29).

No published clinical or animal efficacy studies were found for the tetrasubstituted 'modified GRF(1-29)' sold as CJC-1295 without DAC; it appears in the literature mainly in doping-detection work (not cited here). The relevant evidence is indirect: lab studies showing such substitutions slow GRF(1-29) breakdown, and older small human trials of the unmodified parent peptide GHRH(1-29)NH2.

✓ 2 positive~ 1 mixed? 3 inconclusive

No human safety data exist for the modified analog itself; small trials of the unmodified parent GHRH(1-29) reported no serious adverse effects but these cannot be assumed to transfer.

US compounding: Not compoundable (no pending nomination). Removed from FDA's Category 2 on about April 22, 2026 after its nominations were withdrawn. That doesn't add it to any allowed list, so US pharmacies still can't compound it from bulk ingredient. Status for every peptide.

Browse and filter these papersCJC-1295 (no DAC) prices and vendors

Registered clinical trials

1 trials of CJC-1295 (no DAC) on ClinicalTrials.gov: 0 active, 0 completed. Registered trials include ones that haven't published yet.

TrialStatusPhasePeopleSponsor
A Study to Evaluate CJC 1295 in HIV Patients With Visceral ObesityNCT00267527 · started 2005-12TerminatedPhase 2120ConjuChem

All 1 CJC-1295 (no DAC) trials, with countries and recruiting status

Human studies

✓ Positivehuman trialClin Endocrinol (Oxf) · 1994

Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity.

Eighteen children recruited; one withdrawn before 3 monthsOpen treatment study (single group) of GHRH(1-29)NH212 months

Parent peptide, not the modified analog: in 17 short children, twice-daily unmodified GHRH(1-29)NH2 for a year raised height velocity from 4.8 to 7.2 cm/year, with catch-down growth after stopping.

Key resultMean (SD) height velocity rose from 4.8(0.9) cm/year to 7.2(1.6) cm/year after 12 months (P = 0.001)
Studied
Pre-pubertal children with idiopathic short stature (aged 4.3-11.0 years)
Compared with
Own pretreatment height velocity
Main outcome
Height velocity
Authors' conclusion
Twice-daily s.c. GHRH(1-29)NH2 promoted linear growth in short children who were not GH-insufficient; height velocity returned to pretreatment values after stopping.
Limitations
Small, no concurrent control group; effect not sustained after treatment cessation.
PubMed 7955460DOI
~ Mixedhuman trialMetabolism · 1997

Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.

Eleven healthy elderly men (spelled out in the abstract)Open before-and-after treatment study with nightly self-injection; no control group described6 weeks

Parent peptide, not the modified analog: in 11 elderly men, 6 weeks of nightly GHRH(1-29) raised nocturnal GH and improved 2 of 6 strength measures, but did not change IGF-I, body composition or muscle histology.

Key resultNocturnal GH release rose (P < .02) with no change in IGF-I; upright row (P < .02), shoulder press (P < .04) and abdominal crunch (P < .03) improved; DEXA muscle and fat did not change
Studied
Healthy, ambulatory, non-obese men aged 64 to 76 years with low baseline IGF-I
Compared with
Before-treatment baseline
Main outcome
GH secretion, IGF-I, muscle strength and energy metabolism, body composition
Authors' conclusion
Single nightly GHRH 1-29 doses increased GH secretion and improved some measures of muscle strength and endurance without sustained IGF-I or body composition changes, and without significant adverse effects.
Limitations
n = 11, no placebo group stated, many outcomes tested.
PubMed 9005976DOI
✓ Positivehuman trialClin Endocrinol (Oxf) · 1990

Continuous subcutaneous GHRH(1-29)NH2 promotes growth over 1 year in short, slowly growing children.

Eight children treated; five for 1 year, three for 3-6 monthsOpen treatment study with continuous subcutaneous GHRH(1-29)NH2 infusionUp to 1 year

Parent peptide, not the modified analog: in 5 children with partial GH insufficiency, continuous GHRH(1-29)NH2 infusion for a year raised growth velocity from 4.6 to 7.0 cm/year; it fell back after stopping.

Key resultIn the five children treated for 1 year, mean growth velocity rose from 4.6 to 7.0 cm/year (P = 0.04)
Studied
Pre-pubertal children with partial GH insufficiency
Compared with
Own pretreatment growth velocity
Main outcome
Growth velocity and GH secretion
Authors' conclusion
Continuous GHRH(1-29)NH2 was an effective therapy for some short, slowly growing children; further studies are required to establish optimal dosing.
Limitations
Only eight children, no control group; growth returned to pretreatment rates after stopping.
PubMed 2140733DOI

Reviews

? InconclusivereviewSports Med · 2026

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

No new dataNarrative review of approved and unapproved peptides including sermorelin

Narrative review covering CJC-1295 among gray-market peptides: animal results are often favorable but rigorous human safety data are scarce and there is potential for serious harm.

Authors' conclusion
Many unapproved peptides show favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data are scarce and there is potential for serious harm to patients.
Limitations
Covers twelve peptides, not sermorelin alone; no original data.
PubMed 41966639DOI

Animal & lab studies

? Inconclusivein vitroHorm Metab Res · 1991

In vitro stability of growth hormone releasing factor (GRF) analogs in porcine plasma.

Cells / labIn vitro plasma stability assay with HPLC

In pig plasma, GRF(1-29)-NH2 had a 13-minute half-life; Ala15 substitution slightly prolonged it (17 min) and a D-amino acid at position 2 blocked the main cleavage — the rationale behind modified GRF analogs, without testing clinical effects.

Key resultGRF(1-29)-NH2 degraded rapidly in plasma (t1/2 = 13 min); [Ala15] substitution gave t1/2 = 17 min; cyclized analogs reached t1/2 greater than 2 hr
Studied
GRF analogs incubated in porcine plasma (in vitro)
Main outcome
Plasma half-life and degradation products
Authors' conclusion
GRF(1-29)-NH2 is rapidly cleaved between positions 2 and 3; N-terminal modification, D-amino acid substitution and side-chain cyclization improve plasma stability.
Limitations
In vitro stability assay in porcine plasma, not human pharmacokinetics.
PubMed 1826667DOI
? Inconclusivein vitroBiochim Biophys Acta · 1992

Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs.

Cells / labIn vitro enzyme kinetics by HPLC

Enzyme study showing DPP-IV cleaves GRF(1-29) at Ala2-Asp3 and that position-2 substitutions alter or prevent this cleavage; no biological or clinical outcomes tested.

Studied
GRF analogs with purified human placental dipeptidyl peptidase IV (in vitro)
Main outcome
DPP IV cleavage kinetics at Ala2-Asp3
Authors' conclusion
Results define the S1 selectivity of DPP IV and may help design DPP IV-resistant GRF analogs and DPP IV inhibitors.
Limitations
Purified enzyme kinetics only; no in vivo data.
PubMed 1353684DOI

Verdicts are judged on each paper's own main outcome; grades run from A (strong human evidence) to D (little or none). Details are read from the abstracts, and figures are reproduced only from openly licensed full texts. Not medical advice.